<DOC>
	<DOCNO>NCT01279187</DOCNO>
	<brief_summary>Good bone heal bone build-up necessary success dental implant . Research animal human show drug , call Forteo , increase bone build-up bone strength time . Forteo approve Food Drug Administration ( FDA ) use patient condition bone broken weaken , call osteoporosis . The investigator know , however , whether Forteo effective use human improve bone heal implant placement , whether bone-building bone-strengthening effect patient osteoporosis . This research study do learn effect 7 week treatment Forteo bone build-up strengthen bone patient receive implant .</brief_summary>
	<brief_title>The Impact Parathyroid Hormone ( PTH ) Craniofacial Osseous Regeneration Bone</brief_title>
	<detailed_description>A single center , placebo-controlled , double blind parallel study teriparatide use patient require dental implant therapy plan . Subjects qualify base inclusion/exclusion criterion randomly place one two treatment group , teriparatide ( 20 Î¼g/day ) placebo control . Both patient investigator blind . Serum gingival crevicular fluid ( GCF ) sample , radiograph , tetracycline-labelled bone core constitute main data gather analysis . After implant surgery , patient return 2 week post-operative care 14 week implant impression 16 week receive final restoration . Twelve month implant placement , patient see follow-up exam standardize radiograph ensure proper healing .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Age range 3085 yr Sex : male female ( female subject must postmenopausal , surgically sterilize utilizing birth control abstinence throughout period Teriparatide administration ) Subjects must able willing follow study procedure instruction ; Subjects must read , understood sign informed consent form ; Subjects must need replacement least one tooth mandibular premolar/molar region least 12 month since tooth extraction . Sites must adaptable dental implant placement without necessity grafting . Subjects 30 year 85 year age , Female subject pregnant , lactating , female subject childbearing potential use contraceptive , Subjects metabolic bone diseases Paget 's disease , hypercalcemia ( mild moderate hypocalcemia acceptable entry study ) , moderate severe vitamin D3 abnormality ( If vitamin D level 16 ng/ml patient exhibit interest , dietary supplementation suggest level reevaluate 4 week reconsider inclusion time ) , metabolic bone diseases include osteoporosis , Subjects prior radiation therapy , bone metastasis skeletal malignancy , Subjects medication would affect bone metabolism , Subjects growth hormone deficiency , Subjects uncontrolled diabetes , sprue , inflammatory bowel disease disorder would affect calcium absorption Subjects heavy smoker ( &gt; 1 pack/d ) , Subjects tetracycline sensitivity allergy , Subjects bisphosphonates , Subjects form kidney disease include kidney stone ( urolithiasis nephrolithiasis ) , Subjects know allergy tetracycline and/or demeclocycline ,</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>dental</keyword>
	<keyword>implant</keyword>
</DOC>